The Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States
NCT Number: NCT02526563
The primary investigators in this study plan to investigate serum concentrations of ropivacaine in pediatric patients who already receive as standard of care a continuous wound catheter after an iliac crest alveolar bone graft harvest for completion of a previous cleft palate repair.
The goals of this study are 1) to determine serum concentrations (free, unbound) of ropivacaine 2) To evaluate pain scores during the perioperative period to determine efficacy of wound catheters for postoperative analgesia for iliac crest bone graft harvest.
Looking for future studies?
Notify Me5 year–18 year
All sexes
Observational
Pittsburgh, Pennsylvania, 15213, United States
There have been numerous investigations of serum concentration of ropivicaine using wound catheters in adults. These studies have revealed that wound catheters provide effective analgesia without toxic levels of serum ropivicaine. Our current proposal is different for two reasons. One, the investigators will be investigating the serum levels of ropivacaine in pediatric patients. There are currently no studies investigating the efficacy of this technique in the pediatric population. Two, the wound catheter currently being placed by Dr Losee (and plastic surgeons in other pediatric centers) as part of standard of care is different from other wound catheters. Most wound catheters described in the literature are placed in the surgical wound between muscle and facial planes. The catheter placed by Dr Losee for his routine postoperative pain control is placed adjacent to the periosteum and adjacent to the bone harvest site. Dr Losee has been performing this technique as part of standard patient care and it appears to provide excellent analgesia without side effects from the ropivacaine. However, it is unknown what effect this location has on serum plasma levels of ropivacaine. Measuring unbound ropivacaine will help define whether or not these wound catheters maintain the serum ropivacaine levels below, near, or above toxic levels. Pediatric studies have investigated the serum ropivacaine levels during epidural infusions and peripheral nerve blocks. This local anesthetic is safe as long as the administration is limited to weight based limits. For continuous infusions, ropivacaine should not be administered at a greater rate than 0.4 -0.5 mg/kg/hr. The wound catheters for The Childrens Hospital of Pittsburgh Plastic Surgery service are administered at 0.25 mg/kg/hr. Ropivacaine is the local anesthetic of choice for many pediatric hospitals and for the Acute Interventional Pediatric Pain Service at the Children's Hospital of Pittsburgh because it appears to have a slight safety advantage over bupivacaine. Ropivacaine does not bind sodium channels as avidly as bupivacaine and therefore may not be as cadiac toxic. However, the location of the catheter can alter absorption and may alter plasma levels. Currently there is no data for pediatric iliac crest wound catheters. Since this technique is already a standard of care here at this center, we plan to measure serum ropivacaine levels to define these values.
It is important to understand the dosages currently being used in this pediatric population and the effects on serum local anesthetic levels. When local anesthetic is infused through an epidural, peripheral nerve block, or wound catheter, there is an elevation in local anesthetic plasma levels in the patient. The plasma levels depend on the dose, concentration and location of the catheter. Current literature has defined the plasma levels obtained during continuous infusions of local anesthetic through wound catheters in adults. Safe infusion rates have been defined for adult catheters. This data does not exist for wound catheters in pediatric patients and this study will begin to define these limits. In particular, the catheter currently being placed as standard of care at The Children's Hospital of Pittsburgh is periostial and it is unknown what effect this location has on serum ropivacaine levels
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Blood draws to measure serum ropivicaine
Time frame: three days
Three blood draws
Time frame: Three days
Measure of pain scores for the first three postoperative days
University of Pittsburgh
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07295041
Alveolar Bone Grafting, Implant Placement
Vilnius, Lithuania
View Trial DetailsNCT07272694
Alveolar Bone Grafting, Alveolar Bone Resorption
Pančevo, Serbia
View Trial DetailsNCT07041398
Alveolar Bone Grafting, Bone Gain
Kocaeli, Başiskele, Turkey (Türkiye)
View Trial DetailsNCT06727591
Alveolar Bone Grafting
Alexandria, Egypt
View Trial Details